Form 4: Zymeworks Inc. Executive Leone D. Patterson Reports Stock Option Grant

Leone D. Patterson, EVP, Chief Business and Financial Officer of Zymeworks Inc., reports the acquisition of 360,000 stock options.

Summary

• On September 1, 2024, Leone D. Patterson, the EVP, Chief Business & Financial Officer of Zymeworks Inc., was granted 360,000 stock options.
• The exercise price of these options is $11.73.
• The options vest over time, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in 36 equal monthly installments thereafter.
• The expiration date for these options is August 31, 2034.
• Following this transaction, Patterson directly owns 360,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and value creation.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their executive compensation strategy.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Stakeholder Impact

• The stock option grant could positively impact shareholders by incentivizing the executive to improve company performance and increase shareholder value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates